• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.73% Nasdaq Down1.12%

    Cytori Therapeutics, Inc. (CYTX)

    -NasdaqGM
    0.50 Down 0.03(4.95%) 10:27AM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Cytori Therapeutics, Inc.
    3020 Callan Road
    San Diego, CA 92121
    United States - Map
    Phone: 858-458-0900
    Website: http://www.cytori.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:78

    Business Summary 

    Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. The company markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales representatives, distributors, and partners worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cytori Therapeutics, Inc.

    Corporate Governance 
    Cytori Therapeutics, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 5. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Marc H. Hedrick M.D., 52
    Chief Exec. Officer, Pres, Director and Member of Exec. Committee
    619.00K0.00
    Mr. Tiago Girão , 35
    Chief Financial Officer and VP of Fin.
    129.00K0.00
    Dr. Steven Kesten M.D., 57
    Chief Medical Officer and Exec. VP
    463.00K0.00
    Mr. Seijiro N. Shirahama , 61
    Pres of Asia Pacific
    417.00K0.00
    Mr. John W. Townsend ,
    Chief Accounting Officer and Controller
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders